• Naftifine HCl: Mechanism and Evidence Boundaries

  2026-10-15

  Naftifine HCl is described by APExBIO as an allylamine antifungal agent and squalene 2,3-epoxidase inhibitor. The available product information supports a documented identity and mechanistic rationale, but it does not provide an identity-matched research study, quantitative efficacy results, comparative data, or independent validation of the product’s performance in a defined model.

• How PARP7 Rewires Interferon Signaling in EAE

  2026-10-15

  The 2025 Cell Reports study identified PARP7 as a downstream suppressor of type I interferon signaling: it linked PARP7-dependent ADP-ribosylation of STAT1 and STAT2 to ubiquitination, p62 recruitment, and autophagy-associated protein loss. Genetic or pharmacological PARP7 disruption strengthened interferon-responsive transcription in cells and alleviated symptoms in an EAE mouse model, but the excerpted evidence does not establish clinical efficacy, supplier-specific material performance, or the full in vivo causal pathway.

• Ibrutinib (PCI-32765): BTK Evidence and Scope

  2026-10-14

  A source-grounded overview of Ibrutinib (PCI-32765) as a covalent BTK inhibitor, distinguishing the supplier’s mechanistic and model claims from identity-matched research evidence that is not available here.

• N6-Methyl-dATP: What the Evidence Shows

  2026-10-14

  N6-Methyl-dATP is a modified nucleotide analogue with a plausible role in studying polymerase recognition and methylation-related DNA interactions, but the supplied AML study does not evaluate this compound. Its findings concern the LMO2/LDB1 regulatory axis, so links to DNA replication fidelity, genomic stability epigenetics, or antiviral drug design remain conceptual rather than demonstrated.

• Sex, Angiotensin II, and Mouse Hypertension

  2026-10-13

  Xue and colleagues examined whether biological sex alters angiotensin II-induced hypertension in conscious mice. Their findings associated stronger blood-pressure elevation, altered baroreflex control, and greater autonomic support of blood pressure with male mice, while gonadectomy shifted the responses in both sexes. The study offers mechanistic evidence in a mouse model, but its findings should not be treated as direct evidence for human hypertension or proof that a specific ganglionic blocker caused the observed differences.

• Botulinum Neurotoxin A and Ocular Angiogenesis

  2026-10-13

  A mouse study links botulinum neurotoxin serotype A with reduced laser-induced choroidal neovascularization and implicates neuronal/glial SOCS3 as part of the mechanism. The findings are mechanistically informative but remain preclinical and do not establish clinical efficacy or applicability to human age-related macular degeneration.

• Oleic Acid in Hepatic Ischemia–Reperfusion Research

  2026-10-12

  A 2024 study links Radix Rehmanniae Praeparata extract with improved lipid handling and reduced injury in mouse and hepatocyte models of hepatic ischemia–reperfusion, but the evidence does not isolate Oleic Acid or establish clinical benefit.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-10-11

  Breen et al. describe a drug-sensitized Saccharomyces cerevisiae platform that increases the detectable activity of several TOR/mTOR inhibitors while retaining genetic clues about pathway dependence. The study also reports no evidence of TOR inhibition for Nebivolol hydrochloride and several other tested compounds, illustrating both the screening value and the interpretive limits of a yeast growth model.

• Z-YVAD-FMK: Caspase-1 Inhibitor Evidence

  2026-10-10

  Z-YVAD-FMK is a cell-permeable caspase-1 inhibitor described as irreversible by its product dossier. Its reported use spans pyroptosis research, inflammasome signaling, and apoptosis-related models, but evidence strength differs between vendor-reported observations and peer-reviewed chicken gasdermin findings.

• SLC2A5 Fructose Metabolism in Primary CNS Lymphoma

  2026-10-09

  A 2026 Advanced Science study uses single-cell RNA and B-cell receptor profiling to connect glucose-poor, hypoxic primary CNS lymphoma microenvironments with SLC2A5-mediated fructose metabolism. Its perturbation data identify SLC2A5 as a potential metabolic vulnerability in lymphoma cells and tumor-supportive macrophages, while also linking this metabolic state to T-cell dysfunction.

• Ibrutinib (PCI-32765): Research Evidence and Limits

  2026-10-09

  A source-grounded overview of Ibrutinib research, covering BTK biology, B-cell applications, the distinction between direct and indirect glioma evidence, and important limits on interpreting ATRX-related findings.

• Carbenoxolone Disodium Product Overview

  2026-10-08

  APExBIO lists Carbenoxolone disodium (SKU A8389) as a research compound described as an 11β-hydroxysteroid dehydrogenase inhibitor and gap junction communication modulator. No matched paper evidence is available, so mechanistic and application claims remain supplier-described rather than independently verified.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-10-08

  A 2023 study identifies SMYD2 as a pharmacologically tractable contributor to cisplatin-induced renal fibrosis and inflammation. By combining animal and tubular epithelial cell evidence with two SMYD2-directed inhibitors, the authors connect SMYD2 inhibition with improved renal injury markers, reduced fibrogenic and inflammatory responses, and altered Smad3/STAT3 signaling.

• ABT-199 and Mitochondrial Apoptosis: Evidence Context

  2026-10-07

  A source-grounded overview of ABT-199 (venetoclax) in apoptosis research, placing supplier-described BCL-2 selectivity alongside Harper et al.'s 2025 findings on RNA polymerase II degradation-dependent apoptosis. The evidence, conceptual applications, and limits of cross-mechanistic interpretation are distinguished.

• Dasatinib (BMS-354825) Beyond Target Lists

  2026-10-07

  Dasatinib (BMS-354825) is more than a Src and Bcr-Abl inhibitor in a target catalog. This thought-leadership analysis examines how it can help translational researchers distinguish kinase dependence, adhesion signaling, invasion, and treatment response across cancer models. It connects vendor-described findings in prostate and pancreatic cancer research with a 2024 thymic epithelial tumor study while clearly separating established evidence from forward-looking hypotheses.

7988 records 1/533 page Next 12345 下5页 Last page